Can You Take Wegovy After Mounjaro? Switching Between GLP-1 Medicines

Why would someone switch from Mounjaro to Wegovy in the first place?

People move between weight-management medicines for several reasons. The most common ones our prescribers hear are: side effects that didn't settle after titration, a supply issue at a particular dose, a preference for a different pen format, or simply wanting to try the medicine that has been most discussed in the news. Less often, a person reaches the highest tolerated Mounjaro dose and wants to explore whether a different mechanism suits them better long-term.

It is worth being clear about what switching is not: it is not a sign that treatment has failed. Both Mounjaro (tirzepatide) and Wegovy (semaglutide) are licensed for weight management in UK adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure or type 2 diabetes. If one has produced meaningful results, a prescriber will want to understand the full picture before recommending a change. If results have plateaued, the clinical conversation may go in a different direction entirely. You can read more about how these two medicines compare on our Wegovy vs Mounjaro overview.

The short answer: switching is clinically possible. The longer answer is that the right reason matters as much as the right medicine.

How do the two medicines actually differ, and does that affect the switch?

Mounjaro is a dual GIP and GLP-1 receptor agonist, meaning it activates two gut-hormone pathways involved in appetite regulation and blood-sugar control. Wegovy acts on GLP-1 receptors only. That single-versus-dual mechanism is the core pharmacological difference, and it is one reason the SURMOUNT-5 trial (a head-to-head study published in the New England Journal of Medicine in 2025) found that tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. The STEP 1 trial had already established that semaglutide 2.4mg achieved around 15% average body-weight reduction over 68 weeks, cited by NICE in its appraisal of Wegovy (TA875).

For a switch, this difference matters in one specific way: your tolerability history on Mounjaro does not translate directly. Someone who reached 10mg on Mounjaro without significant nausea will still need to begin Wegovy at its starting dose and titrate upward under prescriber guidance. The titration schedules differ, and restarting at a maintenance-equivalent dose of the new medicine is not appropriate without clinical sign-off. Specific dosing timing is always confirmed by the prescriber and the Patient Information Leaflet for the medicine you are starting.

The side-effect profiles overlap considerably (both are dominated by gastrointestinal effects such as nausea, changes in bowel habit, and reduced appetite) but individual experience varies. The NHS tirzepatide medicines page and the equivalent semaglutide page both give patient-level summaries worth reading before any switch.

What does a prescriber actually assess when you want to make this change?

A transfer of this kind involves more than a prescription for a different pen. At nume, a prescriber reviewing a switch request will look at: your current dose and how long you have been on it; your weight trajectory; the reason for switching; any side effects you experienced; and whether there are clinical reasons to prefer one medicine over the other for your specific health picture. Evidence of your current treatment is part of that assessment.

There is also a practical question about timing. After stopping Mounjaro, its effects on gastric emptying and appetite do not disappear overnight, tirzepatide has a half-life of roughly five days. Our guide to taking Wegovy after Mounjaro covers what to expect in that gap, including why starting at the wrong moment or the wrong dose could compound side effects unnecessarily. Your prescriber sets the timing. This is not a decision to make based on what someone in an online forum did.

The question of taking Mounjaro and Wegovy at the same time is a separate matter entirely, these are not medicines that are combined, and doing so is not clinically appropriate. If you are wondering whether you can take Wegovy with Mounjaro, our dedicated page sets out the clinical reasoning in full.

Which of these suits your situation is a clinical decision our prescribers make with you, not something a comparison table alone can settle. You can explore the broader evidence picture on our detailed Wegovy and Mounjaro comparison page.

How does the process work at nume if you want to switch?

If you are currently on Mounjaro and want to discuss moving to Wegovy, the consultation process is the same as for any new patient, but your transfer history forms part of the review. You will be asked about your current dose, your treatment history, and your reasons for switching. A prescriber reads your answers the same day, checks your ID and weight as part of verification, and makes a clinical decision based on your individual profile.

There is no pressure in either direction. If Mounjaro is working well and the reason for switching is primarily curiosity or cost, a prescriber will say so plainly. If there is a genuine clinical case for Wegovy, the path forward is clear. You can find out more about our clinical team and how consultations work on the about us page. To begin, the free consultation takes a few minutes and is reviewed the same day.